自身免疫病相关慢性创面的研究和治疗进展

张路; 王星童; 褚万立

doi:10.3760/cma.j.cn501225-20220329-00101

自身免疫病相关慢性创面的研究和治疗进展

doi: 10.3760/cma.j.cn501225-20220329-00101

解放军总医院第四医学中心烧伤整形医学部，北京　100048

基金项目:

国家自然科学基金青年科学基金项目 82102320

详细信息

通讯作者:
褚万立，Email：chuwanli@sina.com

计量
- 文章访问数: 111
- HTML全文浏览量: 150
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-29
- 网络出版日期: 2022-08-12
- 刊出日期: 2022-06-20

Advances on the research and treatment of autoimmune disease-related chronic wounds

Department of Burns and Plastic Surgery, the Fourth Medical Center of PLA General Hospital, Beijing 100048, China

Funds:

Youth Science Foundation Project of National Natural Science Foundation of China 82102320

More Information

Corresponding author: Chu Wanli, Email: chuwanli@sina.com

摘要

摘要: 自身免疫病是由于机体免疫系统被错误导向进而攻击宿主自身所引发的一种疾病。该类疾病患者全身状况差，受血管和皮肤组织病变以及治疗药物等的影响，皮肤一旦破溃极易形成迁延不愈的慢性创面，该类创面治疗难度较大，需要多学科医师联合诊疗。基于此，该文对自身免疫病相关慢性创面的研究和治疗进展进行综述，以期为其临床治疗提供参考。
- 自身免疫疾病 /
- 干细胞 /
- 胞外囊泡 /
- 慢性创面 /
- 微小RNA /
- DNA纳米技术
Abstract: Autoimmune disease is a disease caused by the body's immune system being misdirected to attack the host itself. Patients with this type of diseases are in poor general condition, and are affected by vascular and skin tissue lesions, and therapeutic drugs. Once the skin is broken, chronic wounds that do not heal could easily develop. This type of wounds is difficult to treat and requires joint diagnosis and treatment of multidisciplinary physicians. Therefore, this article reviews the advances on research and treatment of autoimmune disease-related chronic wounds in order to provide reference for their clinical treatment.
- Autoimmune diseases /
- Stem cells /
- Extracellular vesicles /
- Chronic wound /
- microRNA /
- DNA nanotechnology

HTML全文

参考文献(54)

[1]	姚泽欣,付小兵,程飚. 慢性创面愈合新理念:姑息性创面治疗的研究进展[J]. 中华烧伤杂志, 2020, 36(8): 754-757. DOI: 10.3760/cma.j.cn501120-20190929-00388.
[2]	PatilS, GsV, SarodeGS, et al. Exploring the role of immunotherapeutic drugs in autoimmune diseases: a comprehensive review[J]. J Oral Biol Craniofac Res, 2021,11(2):291-296. DOI: 10.1016/j.jobcr.2021.02.009.
[3]	ShanmugamVK. Vasculitic diseases and prothrombotic states contributing to delayed healing in chronic wounds[J]. Curr Dermatol Rep, 2016,5(4):270-277. DOI: 10.1007/s13671-016-0157-2.
[4]	FurerV, RondaanC, HeijstekM, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD[J]. RMD Open, 2019,5(2):e001041. DOI: 10.1136/rmdopen-2019-001041.
[5]	ZielinskiMR, SystromDM, RoseNR. Fatigue, sleep, and autoimmune and related disorders[J]. Front Immunol, 2019,10:1827. DOI: 10.3389/fimmu.2019.01827.
[6]	PetriM. Antiphospholipid syndrome[J]. Transl Res, 2020,225:70-81. DOI: 10.1016/j.trsl.2020.04.006.
[7]	JozicI, VukelicS, StojadinovicO, et al. Stress signals, mediated by membranous glucocorticoid receptor, activate PLC/PKC/GSK-3β/β-catenin pathway to inhibit wound closure[J]. J Invest Dermatol, 2017,137(5):1144-1154. DOI: 10.1016/j.jid.2016.11.036.
[8]	CarolinaE, KatoT, KhanhVC, et al. Glucocorticoid impaired the wound healing ability of endothelial progenitor cells by reducing the expression of CXCR4 in the PGE2 pathway[J]. Front Med (Lausanne), 2018,5:276. DOI: 10.3389/fmed.2018.00276.
[9]	MeszarosK, PatocsA. Glucocorticoids influencing Wnt/β-catenin pathway; multiple sites, heterogeneous effects[J]. Molecules, 2020, 25(7):1489. DOI: 10.3390/molecules25071489.
[10]	DixonWG, SuissaS, HudsonM. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses[J]. Arthritis Res Ther, 2011,13(4):R139. DOI: 10.1186/ar3453.
[11]	CordtzRL, ZobbeK, HøjgaardP, et al. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers[J]. Ann Rheum Dis, 2018,77(2):281-288. DOI: 10.1136/annrheumdis-2017-212339.
[12]	KlementMR, PenroseCT, BalaA, et al. How do previous solid organ transplant recipients fare after primary total knee arthroplasty?[J]. J Arthroplasty, 2016,31(3):609-615.e1. DOI: 10.1016/j.arth.2015.10.007.
[13]	MabilleC, DegboeY, ConstantinA, et al. Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha[J]. Joint Bone Spine, 2017,84(4):441-445. DOI: 10.1016/j.jbspin.2016.06.011.
[14]	姜玉峰中国体表慢性难愈合创面流行病学研究北京中国人民解放军军医进修学院2011 姜玉峰. 中国体表慢性难愈合创面流行病学研究[D].北京:中国人民解放军军医进修学院, 2011.
[15]	ShanmugamVK, AngraD, RahimiH, et al. Vasculitic and autoimmune wounds[J]. J Vasc Surg Venous Lymphat Disord, 2017,5(2):280-292. DOI: 10.1016/j.jvsv.2016.09.006.
[16]	JebakumarAJ, UdayakumarPD, CrowsonCS, et al. Occurrence and effect of lower extremity ulcer in rheumatoid arthritis--a population-based study[J]. J Rheumatol, 2014,41(3):437-443. DOI: 10.3899/jrheum.130392.
[17]	WienkeJ, DeakinCT, WedderburnLR, et al. Systemic and tissue inflammation in juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools[J]. Front Immunol, 2018,9:2951. DOI: 10.3389/fimmu.2018.02951.
[18]	RuaroB, BruniC, WadeB, et al. Laser speckle contrast analysis: functional evaluation of microvascular damage in connective tissue diseases. Is there evidence of correlations with organ involvement, such as pulmonary damage?[J]. Front Physiol, 2021,12:710298. DOI: 10.3389/fphys.2021.710298.
[19]	LimYL, BohelayG, HanakawaS, et al. Autoimmune pemphigus: latest advances and emerging therapies[J]. Front Mol Biosci, 2021,8:808536. DOI: 10.3389/fmolb.2021.808536.
[20]	LouF, SunY, XuZ, et al. Excessive polyamine generation in keratinocytes promotes self-RNA sensing by dendritic cells in psoriasis[J]. Immunity, 2020,53(1):204-216.e10. DOI: 10.1016/j.immuni.2020.06.004.
[21]	ZhangLJ. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis[J]. Front Immunol, 2019,10:1440. DOI: 10.3389/fimmu.2019.01440.
[22]	CampanatiA, MaraniA, MartinaE, et al. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches[J]. Biomedicines, 2021, 9(11):1511.DOI: 10.3390/biomedicines9111511.
[23]	ShanmugamVK, DeMariaDM, AttingerCE. Lower extremity ulcers in rheumatoid arthritis: features and response to immunosuppression[J]. Clin Rheumatol, 2011,30(6):849-853. DOI: 10.1007/s10067-011-1710-9.
[24]	BrownM, O'ReillyS. The immunopathogenesis of fibrosis in systemic sclerosis[J]. Clin Exp Immunol, 2019,195(3):310-321. DOI: 10.1111/cei.13238.
[25]	GiuggioliD, ManfrediA, LumettiF, et al. Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature[J]. Autoimmun Rev, 2018,17(2):155-164. DOI: 10.1016/j.autrev.2017.11.020.
[26]	YangSH, ChangC, LianZX. Polymyositis and dermatomyositis-challenges in diagnosis and management[J]. J Transl Autoimmun, 2019,2:100018. DOI: 10.1016/j.jtauto.2019.100018.
[27]	ManuelRC, PilarBZ, RaphaèleS, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements[J]. Rheumatology (Oxford), 2017,56(7):1245. DOI: 10.1093/rheumatology/kex157.
[28]	GoodmanSM, SpringerB, GuyattG, et al. 2017 American college of rheumatology/American association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty[J]. Arthritis Rheumatol, 2017,69(8):1538-1551. DOI: 10.1002/art.40149.
[29]	Kowal-BieleckaO, FransenJ, AvouacJ, et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017,76(8):1327-1339. DOI: 10.1136/annrheumdis-2016-209909.
[30]	RozinAP, EgoziD, RamonY, et al. Large leg ulcers due to autoimmune diseases[J]. Med Sci Monit, 2011,17(1):CS1-7. DOI: 10.12659/msm.881308.
[31]	StevensNE, CowinAJ, KopeckiZ. Skin barrier and autoimmunity-mechanisms and novel therapeutic approaches for autoimmune blistering diseases of the skin[J]. Front Immunol, 2019,10:1089. DOI: 10.3389/fimmu.2019.01089.
[32]	MandelinJ, EklundKK, ReitamoS. Leg ulcers treated with topical tacrolimus in patients with rheumatoid arthritis[J]. Acta Derm Venereol, 2010,90(6):633-634. DOI: 10.2340/00015555-0973.
[33]	StarnoniM, PappalardoM, SpinellaA, et al. Systemic sclerosis cutaneous expression: management of skin fibrosis and digital ulcers[J]. Ann Med Surg (Lond), 2021,71:102984. DOI: 10.1016/j.amsu.2021.102984.
[34]	HayashidaK, YamakawaS. Topical odour management in burn patients[J/OL]. Burns Trauma, 2021,9:tkab025[2022-02-23]. https://pubmed.ncbi.nlm.nih.gov/34458382/. DOI: 10.1093/burnst/tkab025.
[35]	谭谦, 徐晔. 慢性创面治疗的理论和策略[J].中华烧伤杂志,2020,36(9):798-802. DOI: 10.3760/cma.j.cn501120-20200728-00361.
[36]	BattistiA, BraccioliniV, TerenziV, et al. Free flaps in head and neck reconstruction in patients affected by vasculitis: to risk or not to risk?[J]. Oral Oncol, 2019,90:145-146. DOI: 10.1016/j.oraloncology.2018.12.012.
[37]	Morales-PerezMJ, Gallardo-CaleroI, Rivas-NicollsD, et al. Reconstruction of COVID-19 vasculitis-related thumb necrosis with a microsurgical free flap[J]. Microsurgery, 2021,41(4):393-395. DOI: 10.1002/micr.30719.
[38]	ChihabyN, OrliaguetM, Le PottierL, et al. Treatment of Sjögren's syndrome with mesenchymal stem cells: a systematic review[J]. Int J Mol Sci, 2021, 22(19):10474. DOI: 10.3390/ijms221910474.
[39]	HolzerU, van Royen-KerkhofA, van der TorreP, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis[J]. Scand J Rheumatol, 2010,39(1):88-92. DOI: 10.3109/03009740903096622.
[40]	PignattiM, SpinellaA, CocchiaraE, et al. Autologous fat grafting for the oral and digital complications of systemic sclerosis: results of a prospective study[J]. Aesthetic Plast Surg, 2020,44(5):1820-1832. DOI: 10.1007/s00266-020-01848-2.
[41]	MaioneF, CappellanoG, BellanM, et al. Chicken-or-egg question: which came first, extracellular vesicles or autoimmune diseases?[J]. J Leukoc Biol, 2020,108(2):601-616. DOI: 10.1002/JLB.3MR0120-232R.
[42]	GriecoGE, FignaniD, FormichiC, et al. Extracellular vesicles in immune system regulation and type 1 diabetes: cell-to-cell communication mediators, disease biomarkers, and promising therapeutic tools[J]. Front Immunol, 2021,12:682948. DOI: 10.3389/fimmu.2021.682948.
[43]	NarauskaitėD, VydmantaitėG, RusteikaitėJ, et al. Extracellular vesicles in skin wound healing[J]. Pharmaceuticals (Basel), 2021, 14(8):811. DOI: 10.3390/ph14080811.
[44]	HuP, YangQ, WangQ, et al. Mesenchymal stromal cells-exosomes: a promising cell-free therapeutic tool for wound healing and cutaneous regeneration[J/OL]. Burns Trauma, 2019,7:38[2022-02-23]. https://pubmed.ncbi.nlm.nih.gov/31890717/. DOI: 10.1186/s41038-019-0178-8.
[45]	JiaY, WeiY. Modulators of microRNA function in the immune system[J]. Int J Mol Sci, 2020,21(7):2357. DOI: 10.3390/ijms21072357.
[46]	ZhangJ, TanH, CaoQ, et al. Meta-analysis of miRNA variants associated with susceptibility to autoimmune disease[J]. Dis Markers, 2021,2021:9978460. DOI: 10.1155/2021/9978460.
[47]	LiL, ZuoX, LiuD, et al. The profiles of miRNAs and lncRNAs in peripheral blood neutrophils exosomes of diffuse cutaneous systemic sclerosis[J]. J Dermatol Sci, 2020,98(2):88-97. DOI: 10.1016/j.jdermsci.2020.02.009.
[48]	ZgheibC, HiltonSA, DewberryLC, et al. Use of cerium oxide nanoparticles conjugated with microRNA-146a to correct the diabetic wound healing impairment[J]. J Am Coll Surg, 2019,228(1):107-115. DOI: 10.1016/j.jamcollsurg.2018.09.017.
[49]	LiJ, WeiM, LiuX, et al. The progress, prospects, and challenges of the use of non-coding RNA for diabetic wounds[J]. Mol Ther Nucleic Acids, 2021,24:554-578. DOI: 10.1016/j.omtn.2021.03.015.
[50]	ZhangS, ChengZ, WangY, et al. The risks of miRNA therapeutics: in a drug target perspective[J]. Drug Des Devel Ther, 2021,15:721-733. DOI: 10.2147/DDDT.S288859.
[51]	LouD, LuoY, PangQ, et al. Gene-activated dermal equivalents to accelerate healing of diabetic chronic wounds by regulating inflammation and promoting angiogenesis[J]. Bioact Mater, 2020,5(3):667-679. DOI: 10.1016/j.bioactmat.2020.04.018.
[52]	MuirePJ, ThompsonMA, ChristyRJ, et al. Advances in immunomodulation and immune engineering approaches to improve healing of extremity wounds[J]. Int J Mol Sci, 2022,23(8) :4074. DOI: 10.3390/ijms23084074.
[53]	GaoS, LiY, XiaoD, et al. Tetrahedral framework nucleic acids induce immune tolerance and prevent the onset of type 1 diabetes[J]. Nano Lett, 2021,21(10):4437-4446. DOI: 10.1021/acs.nanolett.1c01131.
[54]	MaW, ZhanY, ZhangY, et al. The biological applications of DNA nanomaterials: current challenges and future directions[J]. Signal Transduct Target Ther, 2021, 6(1): 351. DOI: 10.1038/s41392-021-00727-9.